The field of canine arthritis treatment has long awaited a major breakthrough, and finally, in 2023, a groundbreaking solution has emerged. Beransa, a new class of treatment, offers hope for improving the quality of life of dogs suffering from arthritis. The potential effectiveness of Beransa has sparked excitement among veterinarians and pet owners alike.
Understanding Beransa:
Beransa, also known as bedinvetmab, is a medication that neutralises nerve growth factor (NGF), a key player in pain perception. As a monoclonal antibody, Beransa has the ability to specifically target and block NGF, potentially providing substantial relief for dogs experiencing arthritis pain. In Australia, Beransa has been approved for use in alleviating pain associated with osteoarthritis in dogs.
Efficacy and Timeline:
Clinical evidence, including a placebo-controlled study conducted by the manufacturer, supports the positive effects of Beransa. According to the study, approximately one in six dogs showed signs of improvement after one week of treatment, increasing to one in two dogs after a month. It's important to note two factors:
- Caregiver Placebo Effect: Like all arthritis treatments, there is a significant caregiver placebo effect. Therefore, maintaining a realistic expectation of Beransa's efficacy for each individual dog is crucial.
- Supplementary Treatments: While Beransa can provide notable benefits, some dogs may require additional arthritis remedies in conjunction with or instead of Beransa.
Dosage and Frequency:
Beransa is administered via monthly subcutaneous injection. We recommend administering at least two doses before determining if drug is effective in your pet. Effects can be seen as quickly as 7 days, however it is common for it to take 30-60 days for the full benefits to be felt by your dog.
Safety and Side Effects:
The risk of side effects with Beransa appears minimal. Rare cases of swelling and heat at the injection site have been reported. Hypersensitivity reactions, although more common in the feline form of the drug, Solensia, are also possible. Compared to traditional drugs like anti-inflammatories, monoclonal antibodies such as Beransa, exemplified by the safety record of Cytopoint, are considered safer due to their natural protein structure, requiring minimal metabolism or detoxification by the liver or kidneys. However, caution is still advised in dogs with liver or kidney disease until specific studies are conducted.
It is essential to avoid using Beransa in breeding, pregnant, or lactating dogs, as well as dogs under 12 months of age, due to NGF's role in fetal and juvenile development.
Compatibility and Cost:
Beransa is generally safe to use in combination with other drugs and during vaccination. However, when multiple treatments are employed, identifying the cause of any adverse effects may become challenging. As for the cost, a single injection of Beransa in 2023 ranges between $90 and $130, comparable to higher-priced anti-inflammatory drugs.
A New Ray of Hope:
While Beransa may not serve as a definitive solution, its introduction brings a welcomed alternative for dogs suffering from arthritis. In cases where other treatments fail or pose safety concerns, Beransa can help maintain a dog's quality of life. The development of monoclonal antibodies represents a step forward in arthritis treatment, providing pet owners with additional time to cherish their ageing companions.
Consulting Your Veterinarian:
If your dog is diagnosed with arthritis, discussing the potential benefits of Beransa with your veterinarian is strongly recommended. They can evaluate your dog's condition, consider the available treatment options, and guide you on whether Beransa may be a suitable choice.